Skip to main content
. 2013 Apr 19;73(6):1071–1078. doi: 10.1136/annrheumdis-2012-202818

Figure 3.

Figure 3

Mean change in outcomes of treatment. Data are expressed as mean (±SD). Dotted line represents COBRA and straight line represents COBRA-light. *p<0.05 compared with COBRA-light. Number of patients DAS44 COBRA: baseline, 81; week 13, 81; week 26, 81. COBRA-light: baseline, 81; week 13, 80; week 26, 81. Number of patients HAQ COBRA: baseline, 80; week 13, 80; week 26, 78. COBRA-light: baseline, 81; week 13, 79; week 26, 80. Number of patients ESR COBRA: baseline, 81; week 13, 80; week 26, 80. COBRA-light: baseline, 81; week 13, 78; week 26, 80. Number of patients CRP COBRA: baseline, 81; week 13, 81; week 26, 78. COBRA-light: baseline, 79; week 13, 78; week 26, 76. p Values: DAS44: baseline, p=0.2; week 13, p=0.3; week 26, p=0.37. HAQ: baseline, p=0.97; week 13, p=0.33; week 26, p=0.52. lnESR: baseline, p=0.94; week 13, p=0.002; week 26, p=0.006. lnCRP: baseline, p=0.82; week 13, p=0.21; week 26, p=0.94. CRP, C-reactive protein; DAS44, 44-joint disease activity score; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; ln, natural logarithm.